Montana has become the first state to establish a regulatory pathway for experimental drugs that operates entirely outside federal FDA authority. As of this week, biotech companies with drugs in early-stage development can apply to Montana's newly created review board for $12,500 to sell treatments directly to consumers, provided their compounds have completed preliminary testing—sometimes involving as few as 10 healthy participants. The mechanism differs fundamentally from existing 'right-to-try' laws, which typically allow individual patients access to experimental treatments after FDA review. Montana's board instead grants blanket approval for commercial sale, creating a novel state-level regulatory framework that no other jurisdiction has attempted. The move represents a significant jurisdictional assertion by Montana into territory traditionally controlled by federal agencies, raising questions about interstate commerce and pharmaceutical oversight standards.
The policy emerged from genuine patient desperation. Families like the DeVaults, whose son Brody experienced severe developmental delays, have exhausted conventional treatment options and see early-access programs as lifelines. However, Montana's approach generates substantial opposition from medical organizations including the American Medical Association and the Infectious Diseases Society of America, which warn that minimal safety data creates significant liability exposure for both patients and the state. Legal experts note Montana could face federal preemption challenges, as pharmaceutical regulation has historically fallen under exclusive federal purview. The state's review board composition remains unclear, with limited disclosure about board members' qualifications or conflict-of-interest policies. Proponents argue the framework accelerates innovation for rare diseases, while critics point to international examples: the European Union's conditional approval pathway, though more rigorous, has generated concerns about post-market safety monitoring when real-world patient populations differ from trial subjects.
The Montana experiment will likely face congressional scrutiny as regulators assess whether state-level pharmaceutical approval threatens the unified federal system. Industry observers expect other states to watch outcomes closely before replicating the model. The Biden administration has not yet issued guidance on federal authority versus state jurisdiction in this space, creating regulatory ambiguity. Biotech advocates argue Montana's lower barriers could accelerate rare-disease treatments to market, while patient safety organizations call for immediate FDA intervention to establish federal standards. Key questions remain unanswered: whether Montana's approach violates the Interstate Commerce Clause, how liability will be assigned if adverse events occur, and whether the state can enforce quality standards on manufacturers. Policymakers in other states are reportedly monitoring Montana's experience, suggesting this decision could reshape pharmaceutical regulation nationwide if not addressed through federal action.